Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the target of unusually large options trading on Thursday. Traders purchased 23,699 call options on the company. This represents an increase of approximately 51% compared to the average daily volume of 15,658 call options.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday. KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th.

Recursion Pharmaceuticals Trading Up 3.5 %

Shares of NASDAQ RXRX traded up $0.25 during midday trading on Friday, reaching $7.49. 24,568,288 shares of the company's stock traded hands, compared to its average volume of 18,530,172. Recursion Pharmaceuticals has a one year low of $5.60 and a one year high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock's 50 day simple moving average is $7.15 and its 200-day simple moving average is $6.90.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to analysts' expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company's revenue was up 147.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.43) earnings per share. On average, research analysts predict that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the transaction, the director now directly owns 7,066,113 shares in the company, valued at $53,985,103.32. The trade was a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. 15.75% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC purchased a new position in shares of Recursion Pharmaceuticals in the 3rd quarter worth approximately $25,000. Decker Retirement Planning Inc. purchased a new position in Recursion Pharmaceuticals in the fourth quarter worth $26,000. Private Trust Co. NA acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth $27,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after purchasing an additional 4,948 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after purchasing an additional 4,091 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.